Table 3.
Baseline characteristics of patients treated with tocilizumab, included in the matched cohort, compared with those treated with tocilizumab, for whom no matched control was found (excluded from the matched cohort).
| Unmatched patients (n74) | Matched patients (n22) | p | |
|---|---|---|---|
| Age (years) | 58.4 | 66.1 | 0.020 |
| Men (%) | 74.3 | 81.8 | 0.470 |
| Obesity (%) | 31.1 | 13,6 | 0.106 |
| CHF (%) | 1.4 | 0 | 1.000 |
| CRF (%) | 9.5 | 13.6 | 0.691 |
| SAHS (%) | 8.1 | 4.5 | 1.000 |
| Saturation (%) | 94.3 | 96.0a | 0.023 |
| Systolic BP (mmHg) | 124.8 | 124.6a | 0.951 |
| Diastolic BP (mmHg) | 71.3 | 70.0a | 0.628 |
| HR (bpm) | 82.5 | 79.1a | 0.262 |
| Temperature (°C) | 37.0 | 37.1a | 0.898 |
| SAFIb | 2.8 | 3.1a | 0.249 |
| Intubated patients (%) | 18.9 | 0 | 0.035 |
| Radiographic involvementc | 2.6 | 1.7a | 0.001 |
| CRP (mg/dL) | 17.6 | 8.9a | 0.001 |
| Urea (mg/dL) | 37.6 | 33.4a | 0.347 |
CHF: congestive heart failure. CRF: chronic renal failure. SAHS: sleep apnea–hypopnea syndrome. BP: blood pressure. HR: heart rate. SAFI: saturation (%)/fraction of inspired O2 (%). CRP: C-reactive protein.
Bold indicates statistically significant results.
First day of admission values (may not coincide with those of the first day entering the matched cohort, sown in Table 1).
Maximum value 4.76, corresponding to 100% saturation with FiO2 of 21%.
Number of affected quadrants in an anteroposterior chest radiograph. Range: 0–4 (0: no involvement; 4: involvement of the upper and lower lobes of both lungs).